TFC Therapeutics

TFC Therapeutics is a biotechnology company founded in 2023 with a focus on developing novel biologics to target and eliminate key drivers of cancer recurrence and metastasis. The company's slogan, "We are a biotechnology company focused on developing novel biologics to target and eliminate key drivers of cancer," encapsulates its mission succinctly. Blending early-stage research with innovative platform design, TFC Therapeutics aims to develop next-generation treatments to eliminate the most resilient cancers and prevent their recurrence. Despite being in the early stages, the company has already attracted significant interest, receiving a Pre Seed Round investment on 17 August 2023. The investment came from a group of prominent investors including Breakout Ventures, Arch Venture Partners, Alumni Ventures Blockchain Fund, and Alexandria Real Estate Equities, underscoring the industry's confidence in TFC Therapeutics' potential. Headquartered in the United States, TFC Therapeutics is poised to make a meaningful impact in the biopharma and biotechnology industries with its innovative approach to combating cancer.